Gene edited or engineered cells can reverse untreatable cancer. These therapeutics are limited to a minute fraction of the diseased population. Indee is developing a simple and scalable microfluidic technology that uses fluid dynamics to deliver gene editing molecules (eg: Crispr-Cas9) to cells with device manufacturing scales up to 10 million per year. We’re actively unlocking gene therapy for the masses.
Check out this interview with CEO Ryan Pawell